322 related articles for article (PubMed ID: 31277966)
1. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
[TBL] [Abstract][Full Text] [Related]
2. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clayton AH; Althof SE; Kingsberg S; DeRogatis LR; Kroll R; Goldstein I; Kaminetsky J; Spana C; Lucas J; Jordan R; Portman DJ
Womens Health (Lond); 2016 Jun; 12(3):325-37. PubMed ID: 27181790
[TBL] [Abstract][Full Text] [Related]
3. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA; Clayton AH; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Simon JA
Obstet Gynecol; 2019 Nov; 134(5):899-908. PubMed ID: 31599840
[TBL] [Abstract][Full Text] [Related]
4. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
Simon JA; Kingsberg SA; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Clayton AH
Obstet Gynecol; 2019 Nov; 134(5):909-917. PubMed ID: 31599847
[TBL] [Abstract][Full Text] [Related]
6. Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women.
Pyke RE; Clayton AH
J Sex Med; 2019 Dec; 16(12):1885-1894. PubMed ID: 31678098
[TBL] [Abstract][Full Text] [Related]
7. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Koochaki P; Revicki D; Wilson H; Pokrzywinski R; Jordan R; Lucas J; Williams LA; Sadiq A; Krop J
J Womens Health (Larchmt); 2021 Apr; 30(4):587-595. PubMed ID: 33538638
[No Abstract] [Full Text] [Related]
8. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.
Derogatis LR; Komer L; Katz M; Moreau M; Kimura T; Garcia M; Wunderlich G; Pyke R;
J Sex Med; 2012 Apr; 9(4):1074-85. PubMed ID: 22248038
[TBL] [Abstract][Full Text] [Related]
9. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
Mayer D; Lynch SE
Ann Pharmacother; 2020 Jul; 54(7):684-690. PubMed ID: 31893927
[No Abstract] [Full Text] [Related]
10. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
Katz M; DeRogatis LR; Ackerman R; Hedges P; Lesko L; Garcia M; Sand M;
J Sex Med; 2013 Jul; 10(7):1807-15. PubMed ID: 23672269
[TBL] [Abstract][Full Text] [Related]
11. Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials.
Simon JA; Thorp J; Millheiser L
J Womens Health (Larchmt); 2019 Jun; 28(6):769-777. PubMed ID: 30707049
[No Abstract] [Full Text] [Related]
12. Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study.
Portman DJ; Brown L; Yuan J; Kissling R; Kingsberg SA
J Sex Med; 2017 Jun; 14(6):834-842. PubMed ID: 28583342
[TBL] [Abstract][Full Text] [Related]
13. Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study.
Simon JA; Derogatis L; Portman D; Brown L; Yuan J; Kissling R
J Sex Med; 2018 Mar; 15(3):387-395. PubMed ID: 29502984
[TBL] [Abstract][Full Text] [Related]
14. Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.
Derogatis LR; Revicki DA; Rosen RC; Jordan R; Lucas J; Spana C
J Patient Rep Outcomes; 2021 Sep; 5(1):100. PubMed ID: 34559353
[TBL] [Abstract][Full Text] [Related]
15. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.
Goldfischer ER; Breaux J; Katz M; Kaufman J; Smith WB; Kimura T; Sand M; Pyke R
J Sex Med; 2011 Nov; 8(11):3160-72. PubMed ID: 21933348
[TBL] [Abstract][Full Text] [Related]
16. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Spielmans GI; Ellefson EM
J Sex Res; 2024 May; 61(4):540-561. PubMed ID: 36809187
[TBL] [Abstract][Full Text] [Related]
17. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder.
Derogatis L; Clayton A; Lewis-D'Agostino D; Wunderlich G; Fu Y
J Sex Med; 2008 Feb; 5(2):357-64. PubMed ID: 18042215
[TBL] [Abstract][Full Text] [Related]
18. Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin.
Simon JA; Clayton AH; Kim NN; Patel S
Sex Med; 2022 Feb; 10(1):100476. PubMed ID: 34999484
[TBL] [Abstract][Full Text] [Related]
19. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.
Clayton AH; Lucas J; DeRogatis LR; Jordan R
Clin Ther; 2017 Mar; 39(3):514-526.e14. PubMed ID: 28189361
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.
Thorp J; Simon J; Dattani D; Taylor L; Kimura T; Garcia M; Lesko L; Pyke R;
J Sex Med; 2012 Mar; 9(3):793-804. PubMed ID: 22239862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
